The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms. Amongst patients with skin disease, there is significant interest in using complementary alternative medicine and vitamins to treat their disease. Previous human case reports suggest that riboflavin, commonly known as Vitamin B2, is clinically effective for the treatment of psoriasis; however, they were not conclusive. More recent human trials have shown that 400 mg of daily oral riboflavin is a safe and well-tolerated medication to administer to humans. For the purpose of this study, the riboflavin is used as an investigational drug.

Clinical Trial Description

The purpose of this investigation is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Up to fifty volunteers with chronic plaque psoriasis will be recruited for a double-blind, placebo-controlled 28 week prospective study with cross-over of both the intervention and control groups at the 12 week time mark. There will be a 4 week washout period when subjects crossover. Riboflavin will be dosed 400 mg by mouth daily versus placebo. Throughout the study the investigators will perform both clinical and laboratory assessments to measure response. ;

Study Design

Related Conditions & MeSH terms

Psoriasis

Clinical Trial Details

NCT number	NCT02622386
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	Phase 2
Start date	August 11, 2016
Completion date	April 6, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03236870` - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed	`NCT00078819` - Etanercept (Enbrel®) in Psoriasis - Pediatrics	Phase 3
Completed	`NCT04841187` - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting	`NCT03927352` - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis	Phase 3
Completed	`NCT03284879` - Post-Marketing Surveillance Study of OTEZLA
Recruiting	`NCT06027034` - Effectiveness of a Digital Health Application for Psoriasis	N/A
Not yet recruiting	`NCT06050330` - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study	N/A
Recruiting	`NCT05744466` - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed	`NCT04149587` - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed	`NCT01384630` - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis	Phase 2
Completed	`NCT03998683` - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis	Phase 3
Terminated	`NCT03556202` - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)	Phase 3
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting	`NCT06077331` - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis	Phase 2
Completed	`NCT04316585` - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants	Phase 1
Completed	`NCT04894890` - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed	`NCT00358384` - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034	Phase 1
Completed	`NCT03757013` - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed	`NCT03265613` - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis	Phase 1/Phase 2
Completed	`NCT05003531` - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis	Phase 2